Aduro BioTech (ADRO) Downgraded by BidaskClub

Aduro BioTech (NASDAQ:ADRO) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Friday, March 29th, BidAskClub reports.

ADRO has been the topic of a number of other research reports. Zacks Investment Research restated a “hold” rating on shares of Aduro BioTech in a report on Monday, December 31st. HC Wainwright reiterated a “buy” rating and set a $8.30 price target on shares of Aduro BioTech in a report on Wednesday, December 19th. Finally, Oppenheimer reiterated a “buy” rating on shares of Aduro BioTech in a report on Tuesday, March 19th. Two analysts have rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $7.68.

ADRO stock traded down $0.03 during midday trading on Friday, reaching $3.38. The stock had a trading volume of 398,221 shares, compared to its average volume of 287,397. The firm has a market capitalization of $269.90 million, a P/E ratio of -2.91 and a beta of 2.06. Aduro BioTech has a 52-week low of $2.34 and a 52-week high of $9.00.

Aduro BioTech (NASDAQ:ADRO) last announced its quarterly earnings data on Wednesday, February 27th. The biotechnology company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.10). Aduro BioTech had a negative net margin of 632.05% and a negative return on equity of 54.84%. As a group, equities research analysts predict that Aduro BioTech will post -0.68 earnings per share for the current year.

In other Aduro BioTech news, CFO Jennifer Lew sold 18,601 shares of Aduro BioTech stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $4.07, for a total value of $75,706.07. Following the completion of the transaction, the chief financial officer now directly owns 139,380 shares of the company’s stock, valued at approximately $567,276.60. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Elsas Andrea Van sold 6,844 shares of Aduro BioTech stock in a transaction dated Tuesday, February 26th. The shares were sold at an average price of $4.25, for a total value of $29,087.00. Following the completion of the transaction, the insider now directly owns 245,638 shares of the company’s stock, valued at $1,043,961.50. The disclosure for this sale can be found here. Insiders have sold a total of 31,526 shares of company stock valued at $128,874 over the last three months. Corporate insiders own 5.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Aduro BioTech by 138.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,402 shares of the biotechnology company’s stock worth $33,000 after buying an additional 7,202 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Aduro BioTech during the fourth quarter worth about $38,000. SG Americas Securities LLC acquired a new position in shares of Aduro BioTech during the fourth quarter worth about $42,000. Cobblestone Capital Advisors LLC NY acquired a new position in shares of Aduro BioTech during the fourth quarter worth about $56,000. Finally, Jane Street Group LLC acquired a new position in shares of Aduro BioTech during the fourth quarter worth about $59,000. 44.82% of the stock is owned by institutional investors.

Aduro BioTech Company Profile

Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.

Featured Article: QQQ ETF

Analyst Recommendations for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.